EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE — NOT FDA APPROVED

Tirzepatide Dosing Protocol: Dual Agonist Research

Also known as: Mounjaro, Zepbound

metabolic

Research Reference Only

This information is for educational purposes only. Tirzepatide is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It represents a new class of medications for diabetes and obesity, showing superior weight loss compared to GLP-1 agonists alone.

Mechanisms of Action

Dual agonist at GIP and GLP-1 receptors
Enhanced insulin secretion vs GLP-1 alone
Superior appetite suppression
Improved lipid metabolism
Enhanced energy expenditure

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLink
SURMOUNT-1 Obesity Trial
published study
15 mgWeekly72 weeksSubcutaneoushuman

Important Warnings

Safety Considerations

  • Boxed warning for thyroid C-cell tumors in rodents
  • Pancreatitis risk
  • Severe gastrointestinal adverse reactions
  • Acute gallbladder disease